<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01794572</url>
  </required_header>
  <id_info>
    <org_study_id>ICO-2012-04</org_study_id>
    <secondary_id>2012-001473-91</secondary_id>
    <nct_id>NCT01794572</nct_id>
  </id_info>
  <brief_title>Phase 1-2 Study of Total Bone Marrow Irradiation With Helicoidal Tomotherapy in 1st Myeloma Relapse</brief_title>
  <acronym>TOMMY</acronym>
  <official_title>Phase 1-2 Study of the Combination of Escalated Total Bone Marrow Irradiation (TBMI) by Helicoidal Tomotherapy and a Fixed High-dose Melphalan (140 mg/m²) Followed by Peripheral Stem Cell Rescue (PSC) in First Relapsed Multiple Myeloma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Cancerologie de l'Ouest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Cancerologie de l'Ouest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In Multiple Myeloma, an adult hematological malignancy, mainly located in the Bone Marrow&#xD;
      (BM), dramatic recent progresses have been observed, thanks to new agents (proteasome&#xD;
      inhibitors and IMIDs). However, at time of first relapse, high-dose therapy followed by Stem&#xD;
      Cell Rescue (SCR) is frequently mandatory as a consolidation in minimal residual disease, to&#xD;
      healthy patients under 65 yo, combining Melphalan (MPH) and/or Total Body Irradiation. Modern&#xD;
      irradiation modalities are now available by the use of HI-ART Tomotherapy system to realize a&#xD;
      Total Bone Marrow Irradiation (TBMI), in order both to limit the dose administered to Organ&#xD;
      at Risk (lungs, oral cavity) and to focus efficacy on BM. In this phase-1 study, the&#xD;
      conditioning regimen before SCR will combine a fixed high-dose MPH (140 mg/m²) and a dose&#xD;
      escalated TBMI, so as to define its Maximal Tolerated Dose (MTD) and the Dose Limiting&#xD;
      Toxicities (DLT). An extended cohort will further in a phase-2 setting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Experimental :&#xD;
&#xD;
      Total Bone Marrow Irradiation (TBMI) is delivered by the Tomotherapy HI-ART machine, in 2&#xD;
      fractions per day during 4 consecutive days from d -6 to d -3. The escalated dose levels are&#xD;
      determined according to a &quot;3x3&quot; modified Fibonacci method and five dose levels will be&#xD;
      explored. The doses per fraction are: 1gy, 1.25gy, 1.5gy, 1.75gy and 2gy, and consequently&#xD;
      the cumulative TBMI doses are: 8gy, 10gy, 12gy, 14gy and 16gy.&#xD;
&#xD;
      Drug : Melphalan is infused intravenously in 30 minutes on day -2 after IV anti-emetics.&#xD;
&#xD;
      Autologous Peripheral Stem Cell Rescue : are re-infused in the central line on day &quot;0&quot; after&#xD;
      adequate premedication.&#xD;
&#xD;
      Despite the recent finding of new drugs (proteasome inhibitors and IMIDs), Multiple Myeloma&#xD;
      still remain uncurable, especially after the first relapse, even in responding disease under&#xD;
      conventional chemotherapy. In the healthy youngest patients (&lt;65 yo), when peripheral stem&#xD;
      cells collection is available, a high-dose therapy is often proposed in consolidation of&#xD;
      complete or very good partial remission: the conditioning regimen usually includes high dose&#xD;
      alkylating agent (mostly Melphalan) and/or Total Body Irradiation. The new Tomotherapy HI-ART&#xD;
      technology allows irradiating on a 1.6m length field all the bone marrow sites together with&#xD;
      optimal respect of the Organ at Risk (lungs, oral cavity, heart, liver, kidneys…). The&#xD;
      proposed phase-1 study will explore the safety and efficacy of escalated dose of Total&#xD;
      Bone-Marrow Irradiation in combination with a fixed dose of Melphalan (140mg/m²), followed by&#xD;
      autologous SCR. To determine the MTD is the main objective of the study, then the toxicity&#xD;
      profile (DLTs) and the RP2D in an extended cohort at the MTD dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low patient recruitement rate and modification of the therapeutic standard&#xD;
  </why_stopped>
  <start_date type="Actual">April 24, 2013</start_date>
  <completion_date type="Actual">January 7, 2020</completion_date>
  <primary_completion_date type="Actual">January 7, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal Tolerated Dose, type of DLTs</measure>
    <time_frame>1 year</time_frame>
    <description>Maximal Tolerated Dose Type of Dose-limiting Toxicities The escalated dose levels are determined according to a &quot;3x3&quot; modified Fibonacci method and five dose levels will be explored. The doses per fraction are: 1gy, 1.25gy, 1.5gy, 1.75gy and 2gy, and consequently the cumulative TBMI doses are: 8gy, 10gy, 12gy, 14gy and 16gy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety profile Recommended Dose for Phase-2 (RDP2)</measure>
    <time_frame>1 year</time_frame>
    <description>Safety profile: acute, short and middle term toxicities Recommended Dose for Phase-2 (RDP2) and Extended Cohort for 14 patients at this dose</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Efficacy expressed as the rate (%) of Complete Response and Very Good Partial Response</measure>
    <time_frame>1 and 2 years</time_frame>
    <description>osteo-medullary PET fixations evaluation by FDG PET-Scan Disease-free survival at 1 year and Overall Survival</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Multiple Myeloma in Relapse</condition>
  <arm_group>
    <arm_group_label>Total BM irradiation dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total Bone Marrow Irradiation (TBMI) is delivered by the Tomotherapy HI-ART machine, in 2 fractions per day during 4 consecutive days from d -6 to d -3. The escalated dose levels are determined according to a &quot;3x3&quot; modified Fibonacci method and five dose levels will be explored. The doses per fraction are: 1gy, 1.25gy, 1.5gy, 1.75gy and 2gy, and consequently the cumulative TBMI doses are: 8gy, 10gy, 12gy, 14gy and 16gy.&#xD;
For Every patients:&#xD;
Drug : Melphalan is infused intravenously in 30 minutes on day -2 after IV anti-emetics.&#xD;
Autologous Peripheral Stem Cell Rescue : are re-infused in the central line on day &quot;0&quot; after adequate premedication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Melphalan: 140 mg/m²is infused intravenously in 30 minutes on day -2 after IV anti-emetics (5-HT3 antagonists).</description>
    <arm_group_label>Total BM irradiation dose</arm_group_label>
    <other_name>Phenylalanin Mustard</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Hematopoietic Stem cell</intervention_name>
    <description>Autologous Peripheral Stem Cell Rescue : 2.5 10^6 CD-34/Kg are re-infused in the central line on day &quot;0&quot; after adequate premedication.</description>
    <arm_group_label>Total BM irradiation dose</arm_group_label>
    <other_name>Hematopoietic stem cell</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Multiple Myeloma in first relapse.&#xD;
&#xD;
          -  In Complete or very good partial remission&#xD;
&#xD;
          -  Available Collected Autologous Peripheral Stem cells: 2.5x106 CD34+/Kg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled visceral disease: kidney, heart, lung, diabetes mellitus&#xD;
&#xD;
          -  Previous Total body irradiation&#xD;
&#xD;
          -  Any previous radiation dose to the spinal cord which could reach to 45gy equivalent,&#xD;
             including the proposed TBMI&#xD;
&#xD;
          -  Amyloidosis&#xD;
&#xD;
          -  Brain localizations&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stéphane A SUPIOT, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancerologie de l'Ouest</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe MOREAU, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, CHU de NANTES</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CLCC Bergonie, service de radiotherapie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Haut-Leveque, service d'Hématologie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CLCC Oscar Lambret, service de radiothérapie</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Claude Huriez, service d'hématologie</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hotel-Dieu, service d'hématologie</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CLCC ICO, service de radiothérapie</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CLCC Paul Strauss, service de radiothérapie</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hautepierre, service d'hématologie</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Wong JY, Rosenthal J, Liu A, Schultheiss T, Forman S, Somlo G. Image-guided total-marrow irradiation using helical tomotherapy in patients with multiple myeloma and acute leukemia undergoing hematopoietic cell transplantation. Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):273-9. doi: 10.1016/j.ijrobp.2008.04.071. Epub 2008 Sep 9.</citation>
    <PMID>18786784</PMID>
  </reference>
  <reference>
    <citation>Somlo G, Spielberger R, Frankel P, Karanes C, Krishnan A, Parker P, Popplewell L, Sahebi F, Kogut N, Snyder D, Liu A, Schultheiss T, Forman S, Wong JY. Total marrow irradiation: a new ablative regimen as part of tandem autologous stem cell transplantation for patients with multiple myeloma. Clin Cancer Res. 2011 Jan 1;17(1):174-82. doi: 10.1158/1078-0432.CCR-10-1912. Epub 2010 Nov 3.</citation>
    <PMID>21047977</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 15, 2013</study_first_submitted>
  <study_first_submitted_qc>February 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2013</study_first_posted>
  <last_update_submitted>January 18, 2021</last_update_submitted>
  <last_update_submitted_qc>January 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Relapse</keyword>
  <keyword>Complete Remission</keyword>
  <keyword>Very Good Partial Remission</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

